Epidemiology of high-risk HPV in Uzbekistan among 44,000 women – genotypes, risk profiles and screening needs in Uzbekistan
Authors:
- Malokhat Palvannazirovna OltievaMOMalokhat Palvannazirovna Oltieva
- Dilfuza Abdullaevna AlievaDADilfuza Abdullaevna Alieva
- Iroda Pulatovna SharipovaISIroda Pulatovna Sharipova
- Jasur Ravshanovich JuraevJJJasur Ravshanovich Juraev
- Erkin Isakovich MusabaevEMErkin Isakovich Musabaev
- Mirzarakhim Mirzakhakimovich BaynazarovMBMirzarakhim Mirzakhakimovich Baynazarov
- Khasanjon Kobiljon Ugli OdilovKOKhasanjon Kobiljon Ugli Odilov
- Nurmuhammad Jaloliddin Ugli JamoliddinovNJNurmuhammad Jaloliddin Ugli Jamoliddinov
- Ulugbek Khudayberdievich MirzaevUMUlugbek Khudayberdievich Mirzaev
Open Access
- 16 December 2025
- journal article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1721
Abstract
Cervical cancer imposes a substantial public health burden in Uzbekistan, yet comprehensive HPV epidemiological data are lacking. This study characterized high-risk HPV prevalence, genotype distribution, risk factors, and screening coverage in three key regions. We analyzed data from 44,497 women aged ≥ 20 years attending gynecological services in Tashkent, Andijan, and Samarkand (2021–2023). Liquid-based cytology and HPV DNA testing for 12 high-risk genotypes were performed. Sociodemographic, reproductive, behavioral, and clinical variables were collected via standardized questionnaires and examination. Multivariable logistic regression identified associated factors of high-risk HPV infection. High-risk HPV was detected in 3,779 women (8.5%), with regional prevalence of 9.2% in Andijan, 8.8% in Tashkent, and 6.5% in Samarkand. Mixed genotype infections comprised 52.8% of cases; HPV-16/18 accounted for 41.1%. Among HPV-positive women undergoing cytology (n = 2,275), 64.1% had negative findings, 14.7% LSIL, 8.4% ASC-US, 6.9% HSIL, 5.1% ASC-H, 0.5% atypical glandular cells, and 0.3% carcinoma. Independent predictors of HPV infection included younger age, single marital status, lower parity, abortion history, and hormonal contraception (all p < 0.05). Foamy vaginal discharge was a significant clinical predictor (adjusted OR 1.53; p < 0.01). Uzbekistan exhibits an intermediate high-risk HPV burden, dominated by vaccine-preventable genotypes, and low screening coverage. Targeted outreach to identified high-risk groups—by age, reproductive history, and clinical features—will optimize resource allocation. These data support accelerated progress toward WHO elimination targets in Uzbekistan. The online version contains supplementary material available at 10.1186/s12879-025-12096-7.Keywords
This publication has 28 references indexed in Scilit:
- Addressing Global Disparities in Cervical Cancer Burden: A Narrative Review of Emerging StrategiesCurrent HIV/AIDS Reports, 2025
- Comprehensive overview of genotype distribution and prevalence of human papillomavirus in cervical lesionsGynecology and Obstetrics Clinical Medicine, 2024
- Prevalence and genotype distribution of HPV6/11/16/18 infections among 180,276 outpatient females from a Women’s and Children’s Central Hospital, 2015–2021, Chengdu, ChinaScientific Reports, 2023
- The recent natural history of human papillomavirus cervical infection in women living with HIV: A scoping review of meta‐analyses and systematic reviews and the construction of a hypothetical modelHIV Medicine, 2023
- Clinical significance of extended high-risk human papillomavirus genotyping and viral load in cervical cancer and precancerous lesionsGynecology and Obstetrics Clinical Medicine, 2023
- Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancerScientific Reports, 2021
- Cervical cancer screening and prevention in Kazakhstan and Central AsiaJournal of Medical Screening, 2020
- Sociodemographic characteristics, sexual behaviour and knowledge about cervical cancer prevention as risk factors for high-risk human papillomavirus infection in Arkhangelsk, North-West RussiaInternational Journal of Circumpolar Health, 2018
- Worldwide burden of cancer attributable to HPV by site, country and HPV typeInternational Journal of Cancer, 2017
- Triage of HPV positive women in cervical cancer screeningJournal of Clinical Virology, 2016